Neuraxial and peripheral misconnection events leading to wrong-route medication errors: a comprehensive literature review

Eugene R Viscusi,1* Vincent Hugo,2 Klaus Hoerauf,2,3 Frederick S Southwick4

ABSTRACT
We conducted a search of the literature to identify case reports of neuraxial and peripheral nervous system misconnection events leading to wrong-route medication errors. This narrative review covers a 20-year period (1999–2019; English-language publications and abstracts) and included the published medical literature (PubMed and Embase) and public access documents. Seventy-two documents representing 133 case studies and 42 unique drugs were determined relevant. The most commonly reported event involved administering an epidural medication by an intravenous line (29.2% of events); a similar proportion of events (27.7%) involved administering an intravenous medication by an epidural line. Medication intended for intravenous administration, but delivered intrathecally, accounted for 25.4% of events. In the most serious cases, outcomes were directly related to the toxicity of the drug that was unintentionally administered. Patient deaths were reported due to the erroneous administration of chemotherapy (n=16), muscle relaxants (n=4), local anesthetics (n=4), opioids (n=1), and antifibrinolytics (n=1). Severe outcomes, including paraplegia, paraparesis, spinal cord injury, and seizures were reported with the following medications: vincristine, gadolinium, diatrizoate meglumine, doxorubicin, and potassium chloride. These case reports confirm that misconnection events leading to wrong-route errors can occur and may cause serious injury. This comprehensive characterization of events was conducted to better inform clinicians and policymakers, and to describe an emergent strategy designed to mitigate patient risk.

INTRODUCTION
Neuraxial and peripheral analgesia are being used in a growing number of indications.1 2 Neuraxial anesthesia commonly supplements general anesthesia, and may serve as the primary anesthetic for surgeries conducted in the mediastinal region and lower extremities. It is applied in intraoperative, postoperative, and peripartum settings, as well as in end-of-life care. Increasingly, neuraxial routes are being used for acute pain therapy, chronic pain management, and diagnostic procedures. Peripheral nerve blocks provide pain control for patients undergoing surgery, and avoid the need for, and adverse effects linked to, opioids and volatile anesthetics.1 2 Given the range of neuraxial and peripheral applications, opportunities for human error are present.

Misconnection events can occur when delivery systems, such as tubes, syringes, or other accessories, are erroneously connected via an unintended route (eg, enteral, intravascular, neuraxial, or respiratory), leading to wrong-route medication administration.3–5 An example would be intravenous medication delivered to the epidural space.3 Misconnections leading to wrong-route medication delivery have been reported across a number of medical specialties, including anesthesiology, emergency medicine, obstetrics, and oncology.6–9 These events have occurred in a variety of settings, including inpatient surgery,10–14 labor and delivery,6 15 and intensive care units.16 17 Because of a lack of organized and publicly available reporting, it is not possible to assess the rate of misconnections wherein the denominator is the total number of catheter-based neuraxial and peripheral procedures.4 18–21 Several published reviews document that tubing misconnections are uncommon,22–24 however, national research and hospital-based analyses confirm that misconnection events occur. For example, between January 2000 and December 2004, reports of more than 300 errors involving inappropriate intravenous/intravascular medication administration errors due to tubing interconnectivity were submitted to the US MEDMARX medication error-reporting database.22 Misconnections have also been reported by the Australian drug error database,24 a hospital in Japan,25 and tertiary care hospitals in South Africa.26 When these errors do occur, they exert a high burden in terms of morbidity and mortality, patient suffering, and expenses.27–29 In 2006, the Institute of Medicine estimated the average cost of managing any type of serious medication error to be US$8750 per preventable adverse drug event.30 These expenses can also include litigation costs and fines to hospitals, as well as increased length of stay and hospitalization costs.19 31–33

The goal of this narrative review is to characterize the current understanding of neuraxial and peripheral nervous system misconnection errors, and to motivate clinicians and health systems to consistently adopt the new International Organization for Standardization’s (ISO) standards.

METHODS
This narrative review is based on a search of the medical literature and public access documents (English-language publications or abstracts) published between January 1, 1999, and September 2019.
30, 2019. Searches were conducted on PubMed and Embase using a Boolean strategy that initially applied US National Library of Medicine Medical Subject Headings (MeSH) terms to identify human cases; subsequently, a comprehensive sequence of MeSH and free-text terms were used to search indexed and non-indexed publications. These terms included: accidental, anaesth*/anesth*, ‘anesthetic incidents’, avoid*, blockade, bore, caudal, connector*, confus*, deadly, ‘drug administration routes’, drug error(s), ‘drug labeling’, ‘drug overdose’, epidural, erroneous*/error*, extradural, faulty, inadvertent infusion, injection, incident monitoring and reporting, interconnect*, intrathecal, intravenous, ‘Luer/Luer lock’, maladminist*, medication error(s), misconnect*, mistake*, mixup/mix-up(s), ‘mode of delivery’, ‘near-miss(es)’, ‘nerve block’, ‘non-Luer’, ‘organisational accidents’, peridural, peripheral, preventable, route, spinal, subarachnoid, syringe, ‘tube/tubing’, uninten*, ‘universal connector’, ‘universal design’, unknowingly, ventricular, ‘wrong ’, and ‘wrong route’. Similar terms were also applied to a general internet search for public access documents. See online supplemental table 1 for a full summary of literature search terms applied.

The literature search was supplemented by bibliographic review of key source documents to identify case reports specific to wrong-route misconnection. Only case reports and other relevant publications that confirmed a misconnection event and noted the name of the drug administered and the patient’s health outcomes were included. Likewise, wrong-route cases attributed to causes other than misconnection (eg, mislabeled medication bags) were not included in the final analysis. Finally, to avoid reporting twice on the same case, source documents were reviewed closely to identify duplicate reports involving the same patient.

Once identified, cases were aggregated and descriptive analyses were conducted. The severity of each event was assessed using the National Reporting and Learning System incident criteria, as follows: (Low) Any unexpected or unintended incident that required extra observation or minor treatment and caused minimal harm to ≥1 person; (Moderate) Any unexpected or unintended incident that resulted in further treatment, possible surgical intervention, or canceling of treatment or transfer to another area, and which caused short-term harm to ≥1 person; (Severe) Any unexpected or unintended incident that caused permanent or long-term harm to ≥1 person; (Death) Any unexpected or unintended event that caused the death of ≥1 person. In addition, the frequency of reported misconnection/ wrong-route events associated with specific drugs, and the drugs associated with high morbidity and mortality rates when administered by the wrong route, were evaluated.

RESULTS

Approximately 200 unique publications were identified for full-text review; of these, 72 documents representing 133 case studies were determined to be relevant, and of these cases, 130 were included in the final case analysis (three were excluded owing to incomplete information regarding precise drug delivery route). Case study sources were published case reports and clinical studies (including journal manuscripts and scientific congress abstracts), as well as national policy alerts that included case study summaries. Case studies were identified from 25 countries and 6 continents (Africa, Asia, Australia/New Zealand, Europe, and North and South America) over a time period spanning from 1999 to 2019.

Of the reviewed documents, the most commonly reported neuraxial misconnection event type involved administration of medications intended for the epidural route by the intravenous route (29.2%, 38/130)10–26 41–47; a similar proportion of events involved the directionally opposite error (ie, administering medications intended for the intravenous route by the epidural route), at 27.7% (36/130)10–14 24–26 41–66 (figure 1).

Figure 1 Neuraxial and peripheral nerve block misconnection errors identified in case reports (N=130) between 1999 and 2019. Intended route unknown for 3 of 133 cases. IV, intravenous; PNB, peripheral nerve block.

Medications intended for intravenous administration have been directly administered by the intrathecal route (25.4%, 33/130) due to misconceptions. Less frequently, the misconception error was the unintentional administration of a peripheral nerve block via the intravenous route (13.1%, 17/130). Two instances each have been described of injecting intravenous drugs into an intraventricular line or into an extraventricular drain.

Although not a misconnection error, there have been instances of peripheral nerve block medications being administered on the wrong side of the body (7.9%, 10/126). Although not a misconnection error, there have been instances of peripheral nerve block medications being administered on the wrong side of the body (7.9%, 10/126).24

The literature search identified 42 unique drugs or other substances injected via a misconnection event leading to wrong-route error; these misconceptions were primarily neuraxial, but also included peripheral neural administration. Table 1 summarizes the 13 drugs with at least two published cases. Drug classes included: contrast agents, general anesthetics, muscle relaxants, antifibrinolytics, nonselective adrenergic agonists, paracentesis, general anesthetics, and nonsteroidal anti-inflammatory drugs.

The greatest number of patient deaths were due to the erroneous administration of vincristine (n = 4), thiocolchicoside (n = 4), and bupivacaine (n = 4). Moderate to severe harm has been caused by the erroneous epidural administration of potassium chloride and oxytocin. Detailed descriptions of the sequence of events in two cases of neuraxial misconceptions are presented in online supplemental table 2.

For most drugs, or drug combinations, identified, there was only a single reported incident of accidental delivery; these drugs are listed in table 2.5 8 9 97 Among these cases, drugs came primarily from the following classes: antibiotics, chemotherapy agents, contrast agents, muscle relaxants other than thiocolchicoside, and opioids. Patient deaths were reported due to the erroneous intrathecal administration of the chemotherapy agent farmorubicin and tramadol. Other drug classes represented include beta blockers, acetylcholinesterase inhibitors, anticholinergics, decongestants, anticonvulsants, and cholinesterase inhibitors. Last, cases were reported involving the wrong-route administration of insulin, mercuricchrome, parenteral nutrition, and sodium chloride.

**DISCUSSION**

This literature search identified published case reports describing neuraxial and peripheral misconception events leading to wrong-route errors over a 20-year period. These events occurred across a range of healthcare settings and specialty areas and primarily involved the inadvertent delivery of drugs intended for intravenous administration via the intrathecal or epidural routes. Both death and serious morbidity (including paraplegia, paraparesis, spinal cord injury, and seizures) were associated with intravenous and neuraxial line misconnection errors. For most drugs identified, there was only a single reported incident of accidental delivery; this finding is similar to the results of previous literature reviews. In the most serious cases, outcomes were directly related to the toxicity of the drug that was inadvertently administered (e.g., vincristine).

The case studies discussed in this narrative review support findings from several national monitoring systems that have evaluated the frequency of wrong-route misconception errors. This research has consistently shown that these events occur, and that outcomes can be severe. For example, data from the US MEDMARX national error-reporting program and the Australian Incident Monitoring Study database suggest that between 1 in 25 and 1 in 250 intravenous-related medication errors are due to misconceptions. Likewise, a retrospective analysis of the French Pharmacovigilance System found that 27 (96%) of 28 cases of neuraxial wrong-route errors resulted in a serious adverse

**Table 1** Number, severity, and route of drug administration errors identified in case reports: drugs with at least two case reports

<table>
<thead>
<tr>
<th>Drug name</th>
<th>Drug class</th>
<th>Events (n)</th>
<th>Incident(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vincristine†‡</td>
<td>Chemotherapy</td>
<td>19</td>
<td>4</td>
</tr>
<tr>
<td>Potassium chloride†‡</td>
<td>N/A</td>
<td>6</td>
<td>5</td>
</tr>
<tr>
<td>Bupivacaine§</td>
<td>Local anesthetic</td>
<td>5</td>
<td>1</td>
</tr>
<tr>
<td>Thiocolchicoside†‡</td>
<td>Muscle relaxant</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>Gadolinium¶</td>
<td>Contrast agent</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>Ropivacaine§</td>
<td>Local anesthetic</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>Vecuronium†</td>
<td>Muscle relaxant</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>Pancuronium†</td>
<td>Pain reliever</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Tranexamic acid†‡</td>
<td>Antifibrinolytic</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Oxycodone†</td>
<td>N/A</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Ephedrine†</td>
<td>Nonselective adrenergic agonist</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Succinylcholine†</td>
<td>General anesthetic</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>Thiopental†</td>
<td>General anesthetic</td>
<td>2</td>
<td></td>
</tr>
</tbody>
</table>

* Incident severity, as defined by the National Reporting and Learning System, is as follows: (Low) An unexpected or unintended event that required extra observation or minor treatment and caused minimal harm to ≥1 person; (Moderate) Any unexpected or unintended incident that resulted in further treatment, possible surgical intervention, canceling of treatment, or transfer to another area, and which caused short-term harm to ≥1 person; (Severe) Any unexpected or unintended incident that caused permanent or long-term harm to ≥1 person; (Death) Any unexpected or unintended event that caused the death of ≥1 person.

† Intravenous to epidural.
‡ Intravenous to intrathecal.
§ Epidural to intravenous.
¶ Intravenous to intraventricular/extraventricular.
N/A, not applicable.
event, and 11 (39%) /28 resulted in patient death. However, these analyses relied primarily on self-reported information, making it impossible to calculate the true incidence of harmful outcomes. During the conduct of this literature review, we observed that the difficulties inherent in collecting error data, including errors that are not noticed or do not result in patient harm, add to the challenge of calculating true incidence. Of note, we observed that research attempting to identify all events using anonymized prospective reporting or observers documented higher rates of error and near-miss events than research that examined only voluntarily reported events.

Universal Luer systems have long been used to securely connect fittings between needles, syringes, and tubing. These connectors serve multiple medication delivery routes, including intravenous, enteral, neuraxial, and respiratory. An unintended consequence of Luer standardization is an increased potential for patient harm or death due to misconnection between administration routes, leading to wrong-route medication administration. Reports of misconnection errors have led to efforts to create new, less error-prone systems. In 2010, the ISO 80369 series provided new standards to replace the universal use of Luer connectors. The ISO 80369 connectors introduce incompatibility between tubing connections serving different body systems and build in a safeguard to eliminate specific types of error. The ISO 80369-6 standard, introduced in 2016, specifies requirements for new Luer-incompatible neuraxial connectors; Luer connectors will continue to be used only for intravenous connections. Neuraxial applications include the administration of medications to neuraxial sites (ie, the spine, intrathecal space, ventricles of the brain, and the epidural, extradural, or peridural spaces), wound infiltration anesthesia delivery, other regional anesthesia procedures, and monitoring or removing cerebrospinal fluid for therapeutic or diagnostic purposes.

Drug administration is the final step in a complex chain of events that includes procurement, storage, and deployment. In the hospital setting, there are several time points where medication error may occur, leading to a patient not receiving the right drug at the right time and the right place. Recognizing the relationship between Luer interconnectivity and medication

<table>
<thead>
<tr>
<th>Drug type, name</th>
<th>Intended route of administration</th>
<th>Actual route of administration</th>
<th>Incident severity*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antibiotics</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cefotiam</td>
<td>Intravenous</td>
<td>IT</td>
<td>Moderate</td>
</tr>
<tr>
<td>Clindamycin</td>
<td>Intravenous</td>
<td>EPI</td>
<td>Low</td>
</tr>
<tr>
<td>Piperacillin-tazobactam</td>
<td>Intravenous</td>
<td>EPI</td>
<td>Moderate</td>
</tr>
<tr>
<td>Rifampicin</td>
<td>Intravenous</td>
<td>IT</td>
<td>Low</td>
</tr>
<tr>
<td>Chemotherapy</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bleomycin</td>
<td>Intravenous</td>
<td>IT</td>
<td>Moderate</td>
</tr>
<tr>
<td>Doxorubicin</td>
<td>Intravenous</td>
<td>IT</td>
<td>Severe</td>
</tr>
<tr>
<td>Farmorubin</td>
<td>Intravenous</td>
<td>IT</td>
<td>Death</td>
</tr>
<tr>
<td>PEG-asparaginase</td>
<td>Intramuscular</td>
<td>IT</td>
<td>Low</td>
</tr>
<tr>
<td>Contrast agents</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diatrizoate meglumine</td>
<td>Intravenous</td>
<td>IT</td>
<td>Moderate</td>
</tr>
<tr>
<td>Iothalame meglumine</td>
<td>Intravenous</td>
<td>IT</td>
<td>Moderate</td>
</tr>
<tr>
<td>Ioxaglate sodium</td>
<td>Intravenous</td>
<td>IT</td>
<td>Moderate</td>
</tr>
<tr>
<td>Ioxitalamate</td>
<td>Intravenous</td>
<td>IT</td>
<td>Moderate</td>
</tr>
<tr>
<td>Muscle relaxants</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cisatracurium</td>
<td>Intravenous</td>
<td>EPI</td>
<td>Moderate</td>
</tr>
<tr>
<td>Pancuronium</td>
<td>Intravenous</td>
<td>EPI</td>
<td>Low</td>
</tr>
<tr>
<td>Opioids</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hydromorphone</td>
<td>Intravenous</td>
<td>EPI</td>
<td>Moderate</td>
</tr>
<tr>
<td>Remifentanil</td>
<td>Intravenous</td>
<td>EPI</td>
<td>Low</td>
</tr>
<tr>
<td>Tramadol</td>
<td>Intravenous</td>
<td>IT</td>
<td>Death</td>
</tr>
<tr>
<td>Other</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Insulin</td>
<td>Intravenous</td>
<td>EPI</td>
<td>Moderate</td>
</tr>
<tr>
<td>Labetalol—beta blocker</td>
<td>Intravenous</td>
<td>IT</td>
<td>Low</td>
</tr>
<tr>
<td>Mercurochrome</td>
<td>TOP</td>
<td>IT</td>
<td>Severe</td>
</tr>
<tr>
<td>Neostigmine + atropine</td>
<td>Intravenous</td>
<td>EPI</td>
<td>Moderate</td>
</tr>
<tr>
<td>Parenteral nutrition</td>
<td>Intravenous</td>
<td>EPI</td>
<td>Moderate</td>
</tr>
<tr>
<td>Phenytoin</td>
<td>Intravenous</td>
<td>ED</td>
<td>Moderate</td>
</tr>
<tr>
<td>Physostigmine (cholinesterase inhibitor)</td>
<td>Intravenous</td>
<td>EPI</td>
<td>Moderate</td>
</tr>
<tr>
<td>Sodium chloride, ketorolac, esomeprazole, cefotaxime</td>
<td>Intravenous</td>
<td>EPI</td>
<td>Low</td>
</tr>
</tbody>
</table>

*Incident severity, as defined by the National Reporting and Learning System, is as follows: (Low) Any unexpected or unintended incident that required extra observation or minor treatment and caused minimal harm to ≥1 person; (Moderate) Any unexpected or unintended incident that resulted in further treatment, possible surgical intervention, or canceling of treatment, or transfer to another area, and which caused short-term harm to ≥1 person; (Severe) Any unexpected or unintended incident that caused permanent or long-term harm to ≥1 person; (Death) Any unexpected or unintended event that caused the death of ≥1 person.

ED, extraventricular drain; EPI, epidural; IT, intrathecal; PEG, polyethylene glycosylated; TOP, topical.
error and adopting new ISO 580369 standards are critical steps in preventing future adverse outcomes.

Limitations

The data reported here are expected to be incomplete and are not intended to provide an estimate of incidence. This is because chronic under-reporting of misconnection events is widely acknowledged, and this literature search was confined to English-language cases. Furthermore, any interpretation of these data must be assessed in context with the relatively low real-world frequency of misconnection complications. When considering the very large number of regional anesthetic procedures performed worldwide, any potential safety intervention would require the treatment of large patient numbers before benefits could be documented. Therefore, it should be acknowledged that it may never be possible to track the true incidence of these events, or the global impact of any specific technologic intervention.

CONCLUSION

This literature review shows that misconnection events occur and can lead to wrong-route errors, with serious consequences. New technological advances are available that may improve patient safety by preventing misconnection events.

Acknowledgements

Assistance with manuscript preparation was provided to the authors by Caitlin Rothermel, MA, MPH of Peloton Advantage, LLC, an OPEN Health company, Parsippany, NJ, USA, and was sponsored by Becton, Dickinson and Company, Franklin Lakes, NJ, USA.

Contributors

All authors participated in the planning, preparation, and critical review of this manuscript and granted final approval for submission.

Funding

This study was funded by Becton, Dickinson and Company.

Competing interests

FSS declares no conflicts of interest. VH and KH are employees of Becton, Dickinson and Company and own stock or stock options in the company. ERV receives consulting fees from AcelRx, Concentric, Heron Therapeutics, Innacoll, Merck, Neumentum, Pfizer, Recro, Salix, and Trevena.

Patient consent for publication

Not required.

Provenance and peer review

Not commissioned; externally peer reviewed.

Data availability statement

Data sharing not applicable as no datasets generated and/or analyzed for this study.

Open access

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, an indication of whether changes were made, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iD

Eugene R Viscusi http://orcid.org/0000-0003-0260-4396

REFERENCES


22 Hicks RW, Becker SC. An overview of intravenous-related medication administration errors as reported to MEDMARX®, a national medication error-reporting program. J Infus Nurs 2006;29:26–7.


## SUPPLEMENTARY APPENDIX

### Supplementary Table 1: PubMed/Embase Literature Search Strategy

<table>
<thead>
<tr>
<th>Search Strategy</th>
</tr>
</thead>
</table>

MeSH, medical subject heading; TIAB, title or abstract.
### Supplementary Table 2: Case Studies of Misconnection Error Leading to Wrong-Route Connection

#### Intrathecal Vincristine Injection in a Child With Acute Lymphocytic Leukemia

A 2002 case report describes the accidental intrathecal injection of vincristine in a 12-year-old girl under treatment for acute lymphocytic leukemia (ALL), with no history of neurologic deficit. Despite immediate recognition of the error and subsequent aggressive treatment, the patient's condition deteriorated until death from myeloencephalopathy occurred on day 83 following the incident.71

On day 1 of the patient's hospital stay, ALL remission was induced using prednisone. On day 2, the following treatment regimen was implemented: intravenous (IV) vincristine and daunoblastine, and intrathecal methotrexate, hydrocortisone, and cytosine arabinoside. During intrathecal administration, 2 mg of vincristine in 20 mL of diluent was also injected. The error was discovered at 30 minutes and treatment was initiated. A lumbar puncture was used to drain 35 mL of cerebrospinal fluid (CSF) and instill 15 mL of lactated Ringer solution, followed by the removal of an additional 15 mL of CSF. The patient was kept sitting upright, then implanted with an Ommaya reservoir and a lumbar subarachnoid catheter.71

The patient tolerated the procedures well, and at 3 hours following the original treatment, was given an infusion of lactated Ringer’s solution with fresh frozen plasma through the Ommaya reservoir, with simultaneous catheter drainage. She was also given oral glutamic acid and pyridoxine, with no apparent effect.71

The patient's neurologic condition then deteriorated, beginning with declining reflex responses, and progressing to confusion, ascending paralysis, respiratory failure, coma, and death on day 83.71 Chemotherapy was continued with good response until the patient's death, with blood and bone marrow free of blast cells and no evidence of leukemia found on postmortem examination.71 The only significant postmortem findings were neuropathologic: the brain, brainstem and spinal cord were soft; the spinal cord showed massive necrosis with total destruction of both grey and white matter; and the cerebellar tissue was extensively damaged.71

#### Injection of High-dose Gadolinium Into Extraventricular Drain in a Middle-aged Man Undergoing Magnetic Resonance Imaging

A 2016 report describes the case of a 59-year-old man undergoing magnetic resonance imaging (MRI) with gadolinium contrast following craniotomy. The accidental administration of gadolinium into the patient's extraventricular drain (EVD) tubing led to severe, irreversible neurological damage.96

The patient originally underwent 2 uneventful surgeries, 2 days apart, to treat a right tentorial meningioma; this included the placement of an EVD.96 For the first 2 days post-craniotomy, the patient had normal intracranial pressure, CSF drain output, and computed tomography results.96 After a routine MRI on day 3, accompanied by the administration of gadolinium 10mL, the patient complained of nausea and became acutely hypertensive. Intracranial pressure readings were 3 to 9 mm Hg, and the patient was alert and oriented, but anxious. His symptoms resolved for the evening with lorazepam and temazepam administration.96

The following morning, the patient’s status noticeably declined; he developed rapidly progressing aphasia, right facial droop, and delirium. A review of the previous night’s MRI and an MRI of the contents of the EVD reservoir bag revealed the presence of intrathecal gadolinium.96 The patient was voluntarily intubated, and intensive treatment was initiated to reduce cerebral edema, prevent seizures, mitigate damage from a left posterior cerebral artery infarct, and keep him sedated.96 The next day, the patient’s neurologic state deteriorated further. Nonconvulsive status epilepticus was identified via
continuous electroencephalography; this was treated with lorazepam. The patient received IV phenytoin and levetiracetam, and had a lumbar drain placed.96

The patient remained comatose with intermittent seizures that were treated with escalated antiepileptic drug doses and adjustments. He received a tracheostomy and gastrostomy and was transferred to a skilled nursing facility after 2 months. At 2 years, the patient was awake but not interactive or communicative with his environment.96

Gadolinium diethylenetriamine penta-acetic acid encephalopathy has been documented in other cases where gadolinium was found in the CSF after intrathecal or intravascular administration, with acute neurological symptom development.96 While not approved by the US Food and Drug Administration, in studies it has been found to be safe for magnetic resonance cisternography and myelography at low levels. In this case, the patient received 50 to 100 times the maximum recommended dose, given under pressure as an IV push.96 The authors recognize the need to replace the Luer connector system with one that will eliminate the possibility of human error.96